New combo therapy aims to boost leukemia fight without harming transplant
NCT ID NCT05507827
First seen Sep 30, 2025 · Last updated Jun 14, 2026 · Updated 30 times
Summary
This early-stage trial tests whether giving specially engineered donor immune cells (CAR T cells) after a stem cell transplant is safe for adults with a high-risk type of B-cell leukemia. About 22 participants will receive the treatment to see if it can help prevent the cancer from coming back without causing severe side effects like graft-versus-host disease. The goal is to improve the body's ability to fight leukemia after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford Cancer Center
Palo Alto, California, 94305, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.